Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520036 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
A Phase 2 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT03520036 is a Phase 2 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 102 participants.
The verdict
NCT03520036, a Phase 2 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.
Interventions
- DRUG Placebo
- DRUG MT-7117 low dose
- DRUG MT-7117 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2019-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520036
The ClinicalTrials.gov registry entry for NCT03520036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03520036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520036 about?
NCT03520036 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria". The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.
What is the current status of trial NCT03520036?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2018-07-05. Estimated completion is 2019-09-28.
What interventions are being tested in trial NCT03520036?
The interventions under investigation include: Placebo (DRUG), MT-7117 low dose (DRUG), MT-7117 high dose (DRUG).
Who is sponsoring clinical trial NCT03520036?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.